03 May BioAscent announced as CRO partner for Medicines Discovery Catapult Virtual R&D group
BioAscent has been selected as one of the world-class CRO partners tasked with delivering support to the UK Medicines Discovery Catapult’s Virtual R&D Discovery Services platform.
The Medicines Discovery Catapult has announced partnerships with a group of leading CROs, with the aim of boosting UK life sciences R&D and international competitiveness by channelling high quality projects through best-in-class service providers.
BioAscent has entered into an agreement with the Medicines Discovery Catapult to provide integrated drug discovery, medicinal chemistry, biosciences and compound management support and services.
This follows a recent collaboration with the Catapult on a project enabling biotechs and SMEs to select and purchase appropriate focused subsets from the Compound Cloud.
Commenting on BioAscent’s selection and the partnership, Mike Piper, Chief Commercial Officer at BioAscent said: “The Virtual R&D Services platform will provide the UK drug discovery industry with a significant boost and will give SMEs in the sector the opportunity to access the best scientific expertise and technology.
“We are looking forward to providing our drug discovery expertise to clients of the Medicines Discovery Catapult, as well as new customers.”
Part of a UK government initiative, the Catapults are a network of world-leading centres designed to transform the UK’s capability for innovation in specific areas and help drive future economic growth.
The Medicine’s Discovery Catapult is a new addition to this network and its Virtual R&D platform forms part of the UK’s Life Sciences Industrial Strategy, focused on maintaining the UK’s strength and increasing the pace of economic growth in this sector.